依普利酮（Inspra）中文说明书

Eplerenone (Inspra) Chinese instructions

[Indications of eplerenone]

1. Congestive heart failure after acute myocardial infarction: Eplerenone can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that this product can also be used for heart failure after acute myocardial infarction and congestive heart failure after acute myocardial infarction;

2. Anti-hypertensive: Eplerenone can be used alone or in combination with other anti-hypertensive drugs for the treatment of hypertension.

[Usage and Dosage of Eplerenone] Dosage after acute myocardial infarction: The starting dose is 25 mg per day. Under conditions acceptable to the patient within 4 weeks, the titrated dose will be adjusted to 50 mg per day. The dose should also be adjusted according to the patient's potassium level.

Hypertension: 50 mg once a day, either alone or in combination with other antihypertensive drugs. For patients with poor response, adjust to 50 mg twice a day. Higher doses are not recommended.

[Adverse reactions of eplerenone]

The main adverse reactions include: cough, diarrhea, abdominal pain, angina, myocardial infarction, proteinuria, headache, dizziness, fatigue, flu-like symptoms, etc.

Other adverse reactions include: gynecomastia, abnormal vaginal bleeding; increased levels of serum potassium, triglycerides, cholesterol, alanine aminotransferase, γ-glutamyl transferase, creatinine, and uric acid, and decreased serum sodium levels.

[Advantages of eplerenone treatment]

(1) For the treatment of heart failure after acute myocardial infarction, combined with standard treatment drugs can reduce the total mortality in the treatment group by 15% (P=0.008);

(2) Eplerenone and enalapril are equally effective in reversing left ventricular hypertrophy and hypertension, with fewer cough side effects, and the combined effect is more obvious;

(3) There are few adverse reactions. Except for the adverse reactions of increased blood potassium, other adverse reactions are no different from the placebo group;

(4) Eplerenone (Inspra) has almost no sex hormone-related side effects of spironolactone.